A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B1351
MAbs.
1905-07;
Chunyin Gu, Xiaodan Cao, Zongda Wang, Xue Hu, Yanfeng Yao, Yiwu Zhou, Peipei Liu, Xiaowu Liu, Ge Gao, Xiao Hu, Yecheng Zhang, Zhen Chen, Li Gao, Yun Peng, Fangfang Jia, Chao Shan, Li Yu, Kunpeng Liu, Nan Li, Weiwei Guo, Guoping Jiang, Juan Min, Jianjian Zhang, Lu Yang, Meng Shi, Tianquan Hou, Yanan Li, Weichen Liang, Guoqiao Lu, Congyi Yang, Yuting Wang, Kaiwen Xia, Zheng Xiao, Jianhua Xue, Xueyi Huang, Xin Chen, Haixia Ma, Donglin Song, Zhongzong Pan, Xueping Wang, Haibing Guo, Hong Liang, Zhiming Yuan, Wuxiang Guan, Su-Jun Deng
| Products/Services Used |
Details |
Operation |
| Custom Vector Construction |
… with specific and strong SARS-CoV-2 RBD-binding activity, … into an expression vector (GenScript).
The antibody production was … with Protein A magnetic beads (GenScript, L00695). The … |
Get A Quote |
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10?days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by conval... More
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10?days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.
B.1.1.7, B.1.351, D614G, JMB2002, SARS-CoV-2, broad-spectrum, neutralizing antibody, phage-to-yeast, rhesus macaque disease model
